The U.S. Department of Health & Human Services (HHS) has recommended that marijuana be moved from Schedule I to Schedule III under federal law. This decision has widespread implications for the cannabis market's trajectory in 2024, touching on diverse areas ranging from policy and business to the very science underpinning such classifications.

The change in classification is not just a regulatory adjustment. For stakeholders in the cannabis industry, this decision signifies an acknowledgment of the drug's potential benefits and a reduction in the perceived risks associated with its consumption.

Benzinga Virtual Events is hosting a comprehensive discussion on September 14 at 11am ET/8am PT, diving deep into the multifaceted implications of this recommendation. With participation from several industry leaders, this virtual event aims to shed light on the science, policy, and business ramifications of the HHS's groundbreaking recommendation. …

Full story available on Benzinga.com

A note to our visitors

This website has updated its privacy policy in compliance with changes to European Union data protection law, for all members globally. We’ve also updated our Privacy Policy to give you more information about your rights and responsibilities with respect to your privacy and personal information. Please read this to review the updates about which cookies we use and what information we collect on our site. By continuing to use this site, you are agreeing to our updated privacy policy.